Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil-9 for HGAIN Recurrence in HIV-positive MSM
NCT03947775Phase 2Not yet recruiting
- Sponsor
- University Health Network
- Start
- Sep 2022
- Primary completion
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant human papillomavirus 9-valent vaccine in anal intraepithelial neoplasia (AIN), sponsored by University Health Network. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
anal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on NCT03947775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03947775.